Patents Assigned to MaxiVax SA
  • Patent number: 11013790
    Abstract: Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as GM-CSF (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 25, 2021
    Assignee: MaxiVAX SA
    Inventor: Nicolas Mach
  • Patent number: 9861689
    Abstract: Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as GM-CSF (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: January 9, 2018
    Assignee: MaxiVax SA
    Inventor: Nicolas Mach
  • Patent number: 9814682
    Abstract: The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunization in humans and animals. These cells can be used for vaccination where they provide the immunomodulator in an active form, in a continuous, non-immunogenic manner in the immediate vicinity of the vaccine antigen(s). The invention also relates to a vaccine composition comprising immuno-protected encapsulated cells producing an immunomodulator and an antigenic component. The invention also relates to a kit comprising a cell as described and an antigenic component. The strategy of the invention is perfectly suited for both cancer immunotherapy and vaccination against infectious agents.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: November 14, 2017
    Assignee: MaxiVax SA
    Inventor: Nicolas Mach